Pharma BD Deal Intelligence

Becton, Dickinson and Company / C.R. Bard Inc.

2017 · Acquisition/Merger · $24.0B · Complete

Announcement Sentiment

100

Strongly positive

Outcome Score

Worked — the deal delivered on its rationale.

Becton Dickinson acquired C.R. Bard for approximately $24 billion in cash and stock ($222.93 in cash and 0.5077 BD shares per Bard share). The combination created a healthcare leader with approximately $16 billion in annualized revenue.

Key facts

Announced Apr 23, 2017
Closed Dec 29, 2017
Deal value $24.0B
Deal type Acquisition/Merger
Key assets Bard vascular access, Oncology products, Urology portfolio

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals